Evidence map›Paper›PMID 38188874›Full record

ArticleFrontiers in nutrition2023

Blood lipids, lipid-regulatory medications, and risk of bladder cancer: a Mendelian randomization study.

Zhang Cheng, Fangdie Ye, Yingchun Liang, Chenyang Xu, Zheyu Zhang, Yuxi Ou, Xinan Chen, Xiyu Dai, Zezhong Mou, Weijian Li and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in nutrition, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Zhang ChengDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Fangdie YeDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Yingchun LiangDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Chenyang XuDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Zheyu ZhangDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Yuxi OuDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Xinan ChenDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Xiyu DaiDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Zezhong MouDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Weijian LiDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Yiling ChenDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Quan ZhouDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Lujia ZouDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Shanhua MaoDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Haowen JiangDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Fudan University · CNHuashan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The influences of blood lipids and lipid-regulatory medications on the risk of bladder cancer have long been suspected, and previous findings remain controversial. We aimed to assess the causality between blood lipids or lipid-regulatory medications and bladder cancer susceptibility by means of a comprehensive Mendelian Randomization (MR) study. Methods: Genetic proxies from genome-wide association studies (GWAS) of four blood lipid traits and lipid-lowering variants in genes encoding the targets of lipid-regulatory medications were employed. The largest ever GWAS data of blood lipids and bladder cancer involving up to 440,546 and 205,771 individuals of European ancestry were extracted from UK Biobank and FinnGen Project Round 6, respectively. A two-sample bidirectional MR study was performed using the inverse variance weighted as the main method. The heterogeneity, horizontal pleiotropy, MR Steiger, and leave-one-out analyses were also conducted as sensitivity tests. Results: There was indicative evidence that genetically predicted low-density lipoprotein cholesterol (LDL-C) affected bladder cancer susceptibility based on 146 single nucleotide polymorphisms (SNPs) with an odds ratio (OR) of 0.776 (95% confidence interval [CI] = 0.625-0.965, Conclusion: This MR study revealed for the first time, using the most recent and comprehensive GWAS data to date, that genetically predicted total cholesterol (TC) and the lipid-lowering effect of lipid-regulatory medications had no causal association with bladder cancer susceptibility. We also verified claims from early studies that low-density lipoprotein cholesterol (HDL-C), LDL-C, and triglyceride (TG) are not related to bladder cancer susceptibility either. The current study indicated that lipid metabolism may not be as important in the tumorigenesis of bladder cancer as previously believed.

Indexed as

bladder cancerblood lipidsFinnGenlipid-regulatory medicationsMendelian randomizationUK Biobank

Identifiers

PMID38188874
PMCPMC10768687
OpenAlexW4390103661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.